00:00My name is John Lacey-Coulson, I'm a consultant colorectal surgeon and I'm the Chief Investigator on the Triomic Trial.
00:05Perfect. And why are we here today? What are these cancer trials?
00:08So we're here really to celebrate two things. One is the opening of the three new clinic rooms that enables us to, gives us the capacity for the first time ever to see all of the patients who are referred on the colorectal cancer urgent susceptibility pathway.
00:21But what we're also doing is the Triomic Trial, which is a scientific study into a new diagnostic device for colorectal cancer.
00:27And this is a new test where we can take a sample in any outpatient clinic to take a small sample of rectal mucus from patients who might have a bowel cancer.
00:38That then goes off to the lab and we can detect those abnormal cancer cells.
00:42So that might mean in the future that most people might not have to have a colonoscopy, which would save the NHS up to a billion pounds a year and could save us a million outpatient clinic appointments per year.
00:52It also means that patients can get the answer much quicker, whether or not they need to have a colonoscopy.
00:58And it also means that we can collect, we can diagnose colorectal cancer at a much earlier stage, which has the potential to save many hundreds of thousands of lives worldwide every year.
01:08Brilliant. You've kind of touched upon this already, but where do you see it in the beginning of time?
01:12Shropshire's the first to trial it.
01:13So in Shropshire, we're developing the new test to prove that it works.
01:18We're developing the algorithm which takes pi in the lab.
01:20Once that algorithm has been developed, then we'll do a multi-centre study across the UK to prove the sensitivity and the specificity to evaluate the performance of the test.
01:29After that, then obviously we'll be applying for NICE approval so that it will become the new investigation for patients on this pathway across the UK.
01:36And then hopefully after that, it will go worldwide and transform colorectal cancer diagnostic pathways across the world.
01:43Yeah. How long has this been in the making then? And how does it feel to be launching it today?
01:47So I've been doing work with Origin for over 10 years now.
01:51This study has actually come to fruition over the last 18 months or so.
01:56We've been collecting samples for the last 10 months.
01:59It might take us another year to fully complete this part of the study.
02:02The other thing we know is that if we can diagnose colorectal cancer at an early stage, it's estimated that we could save 500,000 lives a year by the year 2030, and that's worldwide.
02:17And some of you will have heard me say that's the equivalent of filling Wembley Stadium to capacity five and a half times over every single year with LifeSafe.
02:26Now, with the opening of these three clinic rooms here today, for the first time ever that I'm aware of, we will routinely have enough clinic slots to see all of the patients who are referred on that pathway.
02:40We have never had that before.
02:42Now, these rooms were £300,000 to have built, and so it's only been possible to build those because of the partnership with Origin.
02:49And the partnership with Origin is available to us because of the triemic trial.
02:55And that's because we're testing this new really, really exciting diagnostic technology so that we can take a sample of the rectum mucus and detect abnormal cells from polyps and cancers.
03:06And when we prove that that works, and we will prove that that works, then we will be able to save the NHS a billion pounds a year in treatment costs.
03:15We will save the NHS a million out-of-patient clinic appointments every single year.
03:21Thank you to everybody.
03:23It's very nicely open.
03:25Yay!
03:35My name's Jo Williams, and I'm the Chief Executive at Shrewsbury and Telford Hospital.
03:39What impact will this clinic have for the people of Telford and Telford?
03:42From a patient perspective, the CDC is really easy to get to.
03:48Also, it's not in a hospital setting, so we don't want people concerned about what they see, all the equipment and invasive procedures.
03:57It's a relaxed setting, and they certainly get a smile when they walk in from all the team here as well, which is great to see.
04:02Perfect. Thank you.
04:04And how does it feel to be here today?
04:06I'm really proud to be here today because this will have a huge impact for patients.
04:11As the team have already shared, it's just something that they're saying to people that they're having a colonoscopy and having bowel prep,
04:19which sometimes they have to take time off work.
04:22It's also quite invasive.
04:23And also, it's something that people worry about, and at times people don't turn up for their appointments.
04:27So just trying it, it's so patient-centered, it's fantastic.
04:31Anything else you'd like to mention?
04:33Just a huge thank you to Origin and the team, because actually the NHS relies on partnership, and we couldn't have done this without their support.
04:41Perfect. Thank you.
04:42Perfect. Do you mind just introducing yourself first?
04:44Hi. So I'm Hugo Lywood. I'm CEO and founder of Origin Sciences.
04:49Brilliant. Perfect. How does it work then?
04:51So our hypothesis is very simple. We hypothesized originally that your mucosal stream that starts in your mouth and ends in your rectum,
05:01you're inside of both gastrointestinal tract, but constantly shed material into that stream.
05:05And we hypothesized if we could collect that material, the rectal mucus, from the rectum and extract the DNA and examine that DNA,
05:13could be a very solid diagnostic for colorectal cancer.
05:15And that's proven to be very much the point.
05:18So we developed what we call the Oracle device, contraption for collecting that mucosal sample.
05:24And it comes with a proctoscope and a syringe.
05:27And the test requires no bowel perforation or anything like that.
05:31So the patient can come into somewhere like here, like a CDC.
05:34And the test can be performed by a junior healthcare professional.
05:37And the proctoscope, which is a very standard piece of equipment, is essentially the rectum in a perfectly cordial way.
05:42And what we call the introducer is removed.
05:45And then the syringe is loaded with 80 cc's of air.
05:49The cap is removed from the device.
05:51And the device is loaded onto the syringe, like that.
05:55And then we replace the introducer and proctoscope with the device.
05:59And we simply inflate the small membrane, which touches the rectal wall, picks up the mucus sample on the external surface.
06:05We then withdraw it like that.
06:07And your specimen is now safely contained within the device.
06:10Everything is removed.
06:12So the patient is involved for about 90 seconds.
06:14And then we add a preservative buffer.
06:18And it grips with the device.
06:19We cap that.
06:20And then that becomes the storage and shipping vessel for that specimen.
06:23And that is shipped currently to Cambridge to our research labs, where we perform our magical assays to determine whether patients have disease.
06:31And from here, the patients usually rely on for colonoscopy, so we compare our findings to the actual diagnosis that's found on the patients in colonoscopy in secondary care.
06:40And what we want to do is qualify the need for those colonoscopies ultimately, so that patients who don't need a colonoscopy don't have trouble.
06:47So I plug off the
07:01and then track it with the понимаю machine.
07:03So what we want to do is try to get started.
07:05So let me move around and see how much noise we shape our prosec Laden.
07:07This is how you do wraỡ thời to use this farm.